November 18, 2009

Takeda Pharmaceutical Company Limited

TAK-438 Enters Phase II Clinical Trials
for the Treatment of Reflux Esophagitis

Osaka, Japan, November 18, 2009 - Takeda Pharmaceutical Company Limited (“Takeda”) announced that TAK-438, which is the drug for acid-related diseases, has entered into Phase II clinical trials for the treatment of patients with reflux esophagitis in Japan.

TAK-438, originated by Takeda, is a potassium-competitive acid blocker that suppresses gastric acid secretion by inhibiting the binding of potassium ion (K⁺) to H⁺,K⁺-ATPase; it is a completely different mechanism of action from conventional proton pump inhibitors (“PPIs”). It is anticipated to have a more potent inhibitory effect on gastric acid secretion, a faster onset of action, and a longer lasting effect than PPIs.

“We expect TAK-438 to have greater acid suppression which may provide better clinical efficacy than PPIs which are widely used to treat acid-related diseases,” said Nancy Joseph-Ridge, M.D., General Manager, Pharmaceutical Development Division of Takeda. “We will continue the development of TAK-438 so that we might be able to offer it to patients as an optimal treatment option for the acid-related diseases, including reflux esophagitis, as quickly as possible.”

# # #